US 11,744,899 B2
Pharmaceutical composition containing a hyaluronic acid derivative
Chiaki Takahata, Tokyo (JP); Naoya Yamashita, Tokyo (JP); Naoko Kunii, Tokyo (JP); and Hirotaka Hoshi, Tokyo (JP)
Assigned to SEIKAGAKU CORPORATION, Tokyo (JP)
Appl. No. 17/276,263
Filed by SEIKAGAKU CORPORATION, Tokyo (JP)
PCT Filed Nov. 15, 2019, PCT No. PCT/JP2019/044851
§ 371(c)(1), (2) Date Mar. 15, 2021,
PCT Pub. No. WO2020/101013, PCT Pub. Date May 22, 2020.
Claims priority of application No. 2018-215867 (JP), filed on Nov. 16, 2018.
Prior Publication US 2022/0016255 A1, Jan. 20, 2022
Int. Cl. A61K 47/61 (2017.01); A61K 47/55 (2017.01); A61P 19/02 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); A61K 47/40 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61M 5/178 (2006.01)
CPC A61K 47/61 (2017.08) [A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); A61K 47/40 (2013.01); A61K 47/55 (2017.08); A61P 19/02 (2018.01); A61M 5/178 (2013.01)] 13 Claims
 
1. A pharmaceutical composition, comprising a compound represented by the following formula (1) and a component (A):
the component (A): at least one type of compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1 to C3 mono-alcohol, a C2 to C3 di-alcohol, a C3 to C6 tri-alcohol, a polyalkylene glycol, a γ-lactone, polyvinylpyrrolidone, a chlorogenic acid, and an alkyl sulfate ester, and salts thereof:

OG Complex Work Unit Chemistry
wherein a is 0.01 or more and 0.7 or less, a+b is 1, n is an integer of 25 or more and 25,000 or less, respective constituent disaccharide units may be arranged in a random or block form, and R is each independently a carboxy group or a carboxylate salt group in the respective constituent disaccharide unit.